IL313962A - Dosage and administration regimen for the treatment or prevention of guillan-barré syndrome by the use of the anti-c5 antibody crovalimab - Google Patents

Dosage and administration regimen for the treatment or prevention of guillan-barré syndrome by the use of the anti-c5 antibody crovalimab

Info

Publication number
IL313962A
IL313962A IL313962A IL31396224A IL313962A IL 313962 A IL313962 A IL 313962A IL 313962 A IL313962 A IL 313962A IL 31396224 A IL31396224 A IL 31396224A IL 313962 A IL313962 A IL 313962A
Authority
IL
Israel
Prior art keywords
crovalimab
guillan
antibody
prevention
management
Prior art date
Application number
IL313962A
Other languages
English (en)
Hebrew (he)
Inventor
Simon Bertrand Marie Buatois
Keisuke Gotanda
Kenji Shinomiya
Alexandre Antoine Bernard Sostelly
Antoine Paul Maxence Soubret
Original Assignee
Hoffmann La Roche
Chugai Pharmaceutical Co Ltd
Simon Bertrand Marie Buatois
Keisuke Gotanda
Kenji Shinomiya
Alexandre Antoine Bernard Sostelly
Antoine Paul Maxence Soubret
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche, Chugai Pharmaceutical Co Ltd, Simon Bertrand Marie Buatois, Keisuke Gotanda, Kenji Shinomiya, Alexandre Antoine Bernard Sostelly, Antoine Paul Maxence Soubret filed Critical Hoffmann La Roche
Publication of IL313962A publication Critical patent/IL313962A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A61K2039/507—Comprising a combination of two or more separate antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/10—Immunoglobulins specific features characterized by their source of isolation or production
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Immunology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Neurology (AREA)
  • Dermatology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Epidemiology (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
IL313962A 2022-04-04 2023-04-03 Dosage and administration regimen for the treatment or prevention of guillan-barré syndrome by the use of the anti-c5 antibody crovalimab IL313962A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP22166586 2022-04-04
PCT/EP2023/058605 WO2023194271A1 (en) 2022-04-04 2023-04-03 Dosage and administration regimen for the treatment or prevention of guillan-barré syndrome by the use of the anti-c5 antibody crovalimab

Publications (1)

Publication Number Publication Date
IL313962A true IL313962A (en) 2024-08-01

Family

ID=81327980

Family Applications (1)

Application Number Title Priority Date Filing Date
IL313962A IL313962A (en) 2022-04-04 2023-04-03 Dosage and administration regimen for the treatment or prevention of guillan-barré syndrome by the use of the anti-c5 antibody crovalimab

Country Status (11)

Country Link
US (1) US20250236661A1 (https=)
EP (1) EP4504773A1 (https=)
JP (1) JP2025510490A (https=)
KR (1) KR20240168923A (https=)
CN (1) CN118556078A (https=)
AU (1) AU2023248634A1 (https=)
CA (1) CA3251879A1 (https=)
IL (1) IL313962A (https=)
MX (1) MX2024009673A (https=)
TW (1) TW202346339A (https=)
WO (1) WO2023194271A1 (https=)

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN107207607B (zh) 2014-12-19 2021-05-04 中外制药株式会社 抗-c5抗体及使用方法
US20230303670A1 (en) * 2020-06-24 2023-09-28 Alexion Pharmaceuticals, Inc. Subcutaneous (sc) administration of anti-c5 antibodies for treatment of complement-associated conditions

Also Published As

Publication number Publication date
MX2024009673A (es) 2024-09-11
JP2025510490A (ja) 2025-04-15
AU2023248634A1 (en) 2024-05-16
CA3251879A1 (en) 2023-10-12
US20250236661A1 (en) 2025-07-24
EP4504773A1 (en) 2025-02-12
TW202346339A (zh) 2023-12-01
KR20240168923A (ko) 2024-12-02
WO2023194271A1 (en) 2023-10-12
CN118556078A (zh) 2024-08-27

Similar Documents

Publication Publication Date Title
IL290256A (en) Anti-pd-1 antibody and pharmaceutical use thereof
LT3914617T (lt) Antikūnų prieš c5 dozavimas ir vartojimas gydant atipinį hemolizinį ureminį sindromą (ahus)
EP3746119A4 (en) METHOD OF TREATMENT FOR CANCER OR INFECTION USING A COMBINATION OF ANTI-PD-1 ANTIBODY, ANTI-LAG3 ANTIBODY, AND ANTI-TIGITE ANTIBODY
MX2018012741A (es) Metodos para el tratamiento de pacientes con hipercolesterolemia familiar.
MX2020009862A (es) Composicion farmaceutica para el tratamiento y/o prevencion de cancer.
EP4286411A4 (en) Humanized antibody against tnfr2 and use thereof
EA201891853A1 (ru) Способы лечения или предотвращения атеросклероза путем введения ингибитора angptl3
FI3773689T3 (fi) Antigeenisiä peptidejä syövän ehkäisyyn ja hoitoon
EA201890519A1 (ru) Ингибирующие антитела против pcsk9 для лечения пациентов с гиперлипидемией, подвергающихся аферезу липопротеинов
IL285267A (en) Antibodies that bind to cleaved form of mutant calreticulin, and diagnostic, preventive, or therapeutic agent for myeloproliferative neoplasm
CR20210103A (es) Composición farmacéutica para usarse en el tratamiento o prevención de una enfermedad relacionada con c5 y método para tratar o prevenir una enfermedad relacionada con c5
EP3934962C0 (en) SEATING ARRANGEMENT AND SYSTEMS
EP4053721A4 (en) DEVICE TO PREVENT AND BLOCK THE POSTING OF HARMFUL CONTENT
EP4083069A4 (en) Anti-ox40 antibody and use thereof
IL291661A (en) Dosing for treatment with anti-tigit and anti-pd-l1 antagonist antibodies
EP3988102C0 (en) MEDICATION FOR THE PREVENTION OR TREATMENT OF RHINOVIRUSES INFECTION
IL286437A (en) Materials and methods for enhanced treatment and prevention of biofilms
RU2017111696A (ru) Лечение респираторных состояний ингибиторами Notch
IL288716A (en) Combination therapy comprising an anti-cd19 antibody drug conjugate and a pi3k inhibitor or a secondary agent
EP4375295A4 (en) Antibody drug for prevention or treatment of autoimmune diseases
DK3953393T3 (da) Farmaceutisk kombination af en EP4-antagonist og immun-checkpoint-inhibitorer til behandling af tumorer
IL286415A (en) Monoclonal antibodies for prevention and treatment of herpes simplex viral infections
DK3810279T5 (da) Kombination omfattende anvendelse af en oligopeptidforbindelse og et anti-pd-1- eller pd-l1-antistof til anvendelse til behandling af neoplastiske tilstande
EP4253416A4 (en) ANTI-SIRPALPHA ANTIBODY OR ASSOCIATED ANTIGEN-BINDING FRAGMENT, AND USE THEREOF
IL313962A (en) Dosage and administration regimen for the treatment or prevention of guillan-barré syndrome by the use of the anti-c5 antibody crovalimab